Blog
    Regulatory UpdateFor PhysiciansJuly 27, 2026

    FDA Category 2 Bulk Substances and Peptide Safety Signals

    Review FDA compounding restrictions for BPC-157, TB-500, and GHK-Cu, alongside emerging safety signals for Semaglutide including NAION and pulmonary aspiration.

    Clinical Question

    How have recent FDA regulatory classifications changed the availability of compounded peptides, and what are the primary postmarketing safety signals identified for widely used peptide therapies?

    Evidence Snapshot

    • Regulatory Listings: FDA Category 2 Bulk Substances (as of March 2026).
    • Compounding Status: 503A and 503B restrictions for BPC-157, TB-500, Ipamorelin, and GHK-Cu due to safety and immunogenicity concerns.
    • Safety Data: FAERS postmarketing analysis for Semaglutide (187,757 reports through 2023).
    • Key Trials Referenced: STEP 1 (Weight Loss), SELECT (CV Outcomes), SURMOUNT-1 (Weight Loss), and TRIUMPH-3 (Ongoing Phase III).

    What the Research Shows

    Regulatory Status and Compounding Restrictions

    As of March 2026, the FDA has classified several peptides under Category 2 bulk substances for 503A compounding, citing significant safety risks and a lack of clinical safety data. BPC-157 was designated Category 2 in September 2023 due to immunogenicity concerns, rendering it ineligible for routine compounding. Similarly, TB-500 (Thymosin Beta-4) is listed in Category 2 with the FDA citing immunogenicity risk and a total lack of human exposure data.

    Regulatory shifts occurred in September 2024 for several agents. CJC-1295, AOD-9604, Ipamorelin, and Selank saw their nominations withdrawn and were removed from consideration for compounding eligibility. The FDA cited specific safety issues for CJC-1295, including increased heart rate. Thymosin Alpha-1, while approved in over 35 countries as Zadaxin, remains non-FDA approved and was removed from the 503A list pending advisory review in September 2024.

    Warning letters have been issued to entities such as Tailor Made Compounding (2020) and Predator Nutrition (2020) for the distribution of these substances. GHK-Cu and GHRP-2 are currently listed under 503B Category 2, precluding their use in outsourcing facilities due to immunogenicity concerns.

    Safety Signals and Postmarketing Surveillance

    Safety evaluations of Semaglutide through the FDA Adverse Event Reporting System (FAERS) indicate strong signals for gastrointestinal events, including nausea, vomiting, and delayed gastric emptying. These are currently within the product label, with delayed gastric emptying noted for its potential impact on oral medication absorption and pre-surgical considerations.

    Emerging signals for Semaglutide include:

    • Intestinal Obstruction / Ileus: Added to postmarketing labels.
    • Pulmonary Aspiration: Added to the Ozempic label in 2025; noted risk during general anesthesia.
    • NAION (Nonarteritic Anterior Ischemic Optic Neuropathy): 96 cases detected through December 2024; currently under EMA review (January 2025).
    • Pancreatitis and Cholelithiasis: Moderate signals identified; pancreatitis is a boxed-adjacent warning.

    Clinical Trial Benchmarks

    In Phase III obesity trials, Tirzepatide (SURMOUNT-1) demonstrated a 22.5% weight loss, while Semaglutide (STEP 1) demonstrated 14.9%. Retatrutide, currently in Phase III (TRIUMPH-3), showed 24.2% weight loss at 12mg in Phase II dose-finding studies. In contrast, clinical trial results for Thymosin Alpha-1 in sepsis (NCT02867267) were negative, showing no reduction in mortality.

    Mechanism

    The provided data describes safety-related mechanisms rather than therapeutic pathways. For CJC-1295, the FDA notes a mechanism resulting in increased heart rate. For BPC-157, TB-500, GHK-Cu, and GHRP-2, the primary safety concern cited is the risk of immunogenicity. Semaglutide's safety signals are partially attributed to delayed gastric emptying, which contributes to risks of pulmonary aspiration and altered drug absorption.

    Limitations of the Evidence

    The primary limitation for peptides like TB-500 is the complete absence of human exposure data. For BPC-157, there is a distinct lack of long-term safety data. While FAERS provides volume-based signals for Semaglutide, current data do not support a higher risk of suicidal ideation compared to background rates, though the FDA continues to require monitoring. Thymosin Alpha-1 has regulatory approval in other jurisdictions (Russia, and 35+ other countries) but lacks the requisite safety data for FDA approval. Many compounding status changes resulted from withdrawn nominations, limiting the federal review of these substances.

    Clinical Takeaway

    The regulatory landscape for compounded peptides has tightened significantly, with the FDA placing BPC-157, TB-500, and GHK-Cu into Category 2 due to immunogenicity and safety concerns. For approved GLP-1 RAs, postmarketing surveillance has identified new risks, including pulmonary aspiration and NAION, requiring clinical vigilance during anesthesia and long-term monitoring. Significant variations in weight loss efficacy exist between approved and investigational agents, ranging from 14.9% to 24.2% across different trial phases.

    Sources

    1. FDA Regulatory Status Records (BPC-157, Thymosin Alpha-1, TB-500, AOD-9604, CJC-1295, Ipamorelin, Selank, Semax, GHK-Cu, GHRP-2; March 2026).
    2. FAERS Safety Signals (Semaglutide; Dec 2024/Jan 2025).
    3. Clinical Trial Records (STEP 1, SELECT, SURMOUNT-1, SURMOUNT-5, TRIUMPH-3, STAY Trial, TESTS; 2026).

    This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice.

    Referenced Peptides

    bpc 157semaglutidetirzepatidethymosin alpha 1tb 500

    This content was generated from TruthTides clinical reference data. It does not constitute medical advice. Always consult a qualified healthcare provider.